Correlation Between ABVC Biopharma and Cardiol Therapeutics

Can any of the company-specific risk be diversified away by investing in both ABVC Biopharma and Cardiol Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining ABVC Biopharma and Cardiol Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between ABVC Biopharma and Cardiol Therapeutics Class, you can compare the effects of market volatilities on ABVC Biopharma and Cardiol Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in ABVC Biopharma with a short position of Cardiol Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of ABVC Biopharma and Cardiol Therapeutics.

Diversification Opportunities for ABVC Biopharma and Cardiol Therapeutics

0.29

Correlation Coefficient

ABVC Biopharma  Cardiol Therapeutics

Modest diversification

The 3 months correlation between ABVC and Cardiol is 0.29. Overlapping area represents the amount of risk that can be diversified away by holding ABVC Biopharma and Cardiol Therapeutics Class in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cardiol Therapeutics and ABVC Biopharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on ABVC Biopharma are associated (or correlated) with Cardiol Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cardiol Therapeutics has no effect on the direction of ABVC Biopharma i.e., ABVC Biopharma and Cardiol Therapeutics go up and down completely randomly.

Pair Corralation between ABVC Biopharma and Cardiol Therapeutics

Given the investment horizon of 90 days ABVC Biopharma is expected to generate 1.8 times more return on investment than Cardiol Therapeutics. However, ABVC Biopharma is 1.8 times more volatile than Cardiol Therapeutics Class. It trades about 0.01 of its potential returns per unit of risk. Cardiol Therapeutics Class is currently generating about -0.23 per unit of risk. If you would invest  55.00  in ABVC Biopharma on October 22, 2024 and sell it today you would lose (1.00) from holding ABVC Biopharma or give up 1.82% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

ABVC Biopharma  vs.  Cardiol Therapeutics Class

ABVC Biopharma

Risk-Adjusted Performance

1 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in ABVC Biopharma are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, ABVC Biopharma may actually be approaching a critical reversion point that can send shares even higher in February 2025.

Cardiol Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Cardiol Therapeutics Class has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's fundamental indicators remain quite persistent which may send shares a bit higher in February 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.

Pair Trading with ABVC Biopharma and Cardiol Therapeutics

The main advantage of trading using opposite ABVC Biopharma and Cardiol Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if ABVC Biopharma position performs unexpectedly, Cardiol Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cardiol Therapeutics will offset losses from the drop in Cardiol Therapeutics' long position.

The idea behind ABVC Biopharma and Cardiol Therapeutics Class pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.